ClinicalTrialsFinder

HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer Clinical Trials in Shanghai

1 recruitingShanghai, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

HER2-positive, Unresectable, Locally Advanced or Metastatic Breast CancerSKB264Inetetamab
Fudan University48 enrolled1 locationNCT07182721